04:38 PM EDT, 03/19/2025 (MT Newswires) -- Capricor Therapeutics ( CAPR ) reported a Q4 loss late Wednesday of $0.16 per diluted share, wider than a loss of $0.02 a year earlier.

Analysts polled by FactSet expected a loss of $0.12.

Revenue for the quarter ended Dec. 31 was $11.1 million, down from $12.1 million a year earlier.

Four analysts surveyed by FactSet expected $3.5 million.

The company said its available cash, cash equivalents and marketable securities of $151.5 million as of the end of 2024 will be enough to cover expenses and capital requirements into 2027.